← Back to Search

Enzyme Preparation

ADI-PEG20 for Prediabetes

Phase 2
Waitlist Available
Led By Samuel Klein, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Prediabetes, defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7%, or HOMA-IR ≥2.5
Age: ≥18 and ≤22 years
Must not have
Taking dietary supplements or medications known to affect our study outcomes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 8 weeks of adi-peg20 or placebo
Awards & highlights

Summary

This trial will look at how a new enzyme preparation affects insulin, energy usage & breath in teens with prediabetes.

Who is the study for?
This trial is for young adults aged 18 to 22 with a BMI between 25.0 and 44.9 who have prediabetes, indicated by specific blood sugar levels or insulin resistance markers. It's not open to those on certain meds or supplements, with serious health issues, allergies to the study drugs, metallic implants affecting MRI scans, or diabetes (HbA1C ≥6.5%).
What is being tested?
The study tests if ADI-PEG20 improves how the body uses insulin and energy in adolescents with prediabetes compared to a placebo (a substance with no therapeutic effect). Participants will be randomly assigned to receive either ADI-PEG20 or placebo.
What are the potential side effects?
Possible side effects of ADI-PEG20 may include allergic reactions due to its ingredients and potential unknown risks since it's being tested for new uses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have prediabetes based on my blood sugar or HbA1C levels.
Select...
I am between 18 and 22 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not taking supplements or medications that could interfere with the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 8 weeks of adi-peg20 or placebo
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 8 weeks of adi-peg20 or placebo for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in insulin sensitivity
Secondary study objectives
Change in intrahepatic triglyceride content
Change in muscle mitochondrial respiration
Change in oral glucose tolerance
+2 more
Other study objectives
Change in the transcriptome in adipose tissue
Change in the transcriptome in muscle

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ADI-PEG20Experimental Treatment1 Intervention
ADI-PEG20 (ADI-PEG20 is arginine deiminase (ADI) conjugated to polyethylene glycol (PEG) of 20,000 molecular weight) will be weekly intramuscularly at a dose of 18 mg/m2 body surface area/week for 8-week.
Group II: PlaceboPlacebo Group1 Intervention
Will be weekly intramuscularly for 8-week

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,970 Previous Clinical Trials
2,308,575 Total Patients Enrolled
81 Trials studying Obesity
14,105 Patients Enrolled for Obesity
Polaris Pharmaceuticals, Inc.UNKNOWN
Children's Discovery InstituteOTHER
4 Previous Clinical Trials
427 Total Patients Enrolled

Media Library

ADI-PEG20 (Enzyme Preparation) Clinical Trial Eligibility Overview. Trial Name: NCT05829239 — Phase 2
Obesity Research Study Groups: ADI-PEG20, Placebo
Obesity Clinical Trial 2023: ADI-PEG20 Highlights & Side Effects. Trial Name: NCT05829239 — Phase 2
ADI-PEG20 (Enzyme Preparation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05829239 — Phase 2
~32 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top